Skip to main content
Guobang Pharma Ltd. logo

Guobang Pharma Ltd. — Investor Relations & Filings

Ticker · 605507 ISIN · CNE100004NS2 LEI · 300300PS6T4W4PGYPM51 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 510 across all filing types
Latest filing 2025-10-16 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 605507

About Guobang Pharma Ltd.

https://www.gbgcn.com

Guobang Pharma Ltd. specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and finished dosage forms. The company operates across two primary sectors: human health and animal health. Its product portfolio includes a wide range of anti-infectives, such as macrolides and quinolones, as well as cardiovascular medications and veterinary drugs like florfenicol. Guobang Pharma maintains a comprehensive industrial chain, leveraging large-scale production facilities and advanced chemical synthesis technologies to serve global markets. The organization focuses on providing integrated solutions for pharmaceutical raw materials, emphasizing quality control and regulatory compliance to meet international standards.

Recent filings

Filing Released Lang Actions
独立董事提名人声明与承诺-孔令义
Board/Management Information Classification · 95% confidence The document is a formal statement nominating an independent director candidate for the board of a company, detailing qualifications, compliance with laws and regulations, and declarations of independence and integrity. It does not contain financial data, audit information, or report results. It is related to board/management information, specifically about board nominations and qualifications. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on nomination, not a report or announcement of voting results or governance rules.
2025-10-16 Chinese
内幕信息知情人登记管理制度（2025年10月修订）
Governance Information Classification · 95% confidence The document is a detailed internal policy titled '内幕信息知情人登记管理制度' (Insider Information Insider Registration Management System) issued by Guobang Pharmaceutical Group Co., Ltd. It outlines the management, confidentiality, and regulatory compliance related to insider information and insider persons. It references relevant securities laws and regulatory guidelines, but it is not a financial report, earnings release, or announcement of voting results. It is a governance-related document detailing internal rules and procedures for managing insider information and compliance with securities regulations. Therefore, it fits best under Governance Information (CGR). The document length (5559 characters) and content confirm it is a full policy document, not a brief announcement or certification.
2025-10-16 Chinese
募集资金管理制度（2025年10月修订）
Capital/Financing Update Classification · 95% confidence The document is titled '募集资金管理制度' which translates to 'Fundraising Capital Management System' and details the rules and procedures for the management, storage, and use of funds raised by the company through stock issuance or other equity securities. It references relevant Chinese laws and stock exchange regulations, outlines internal controls, supervisory responsibilities, and disclosure requirements related to the use of raised funds. The document is a detailed policy or procedural manual rather than a financial report, earnings release, or announcement. It does not contain financial statements or results but rather governance and compliance rules regarding fundraising capital. Therefore, it fits best under a regulatory or governance-related filing. Since it is a detailed internal policy document about fundraising capital management, it aligns most closely with Capital/Financing Update (CAP) as it concerns the management and use of capital raised by the company. The document length (7914 characters) and content indicate it is not a brief announcement but a substantive policy document. Hence, the classification is CAP with high confidence.
2025-10-16 Chinese
独立董事候选人声明与承诺-潘自强
Board/Management Information Classification · 95% confidence The document is a declaration and commitment statement by an independent director candidate, detailing qualifications, independence criteria, and compliance with regulatory requirements. It is a formal statement related to board membership candidacy rather than a report, announcement of voting results, or management change notice. It does not contain financial data, audit information, or meeting materials. The content fits best under Board/Management Information (MANG) as it pertains to board candidate qualifications and declarations.
2025-10-16 Chinese
国邦医药关于董事会换届选举的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the election and composition of the company's board of directors, including details about the nomination and qualifications of board candidates. It references the upcoming shareholder meeting for election approval and provides biographical information about the candidates. There is no financial data, earnings information, or report publication mentioned. The content clearly pertains to changes and updates in the company's board of directors. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 3823 characters, which is sufficient for a detailed announcement but not a full report. Hence, the classification is MANG with high confidence.
2025-10-16 Chinese
国邦医药关于股份回购进展公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement from Guobang Pharmaceutical Group Co., Ltd. regarding the progress of its share repurchase program. It details the number of shares repurchased, the price range, total amount spent, and the purpose of the repurchase (employee stock ownership plan or equity incentives). The document references regulatory compliance and previous announcements about the repurchase plan. It does not contain financial statements or earnings data but focuses solely on the share buyback activity. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers company announcements about buying back its own shares.
2025-10-09 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.